| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| XFOR | XFOR | Shares | USD | XNCM |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| XFOR | XFOR | Shares | USD | XNCM |
X4 Pharmaceuticals, Inc. develops and commercializes therapies for rare diseases of the immune system. The company has received U.S. approval for its product XOLREMDI® (mavorixafor) and is advancing this therapy for additional patient populations, including those with chronic neutropenic disorders through a global Phase 3 clinical trial. X4 is headquartered in Boston, Massachusetts.
No recent RNS announcements for XFOR across XFOR.
No recent RNS announcements for XFOR across XFOR.